MEDIUM confidence: 100% data completeness, but the composite (48) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $844M— | $1.0B+22.9% | $1.8B+76.2% | $2.2B+23.0% | $3.7B+65.2% |
| EPS (dil.) | $-7.20— | $-9.30n/m | $-3.52n/m | $-2.18n/m | $2.33n/m |
| Free Cash Flow | -$718M— | -$613Mn/m | $42Mn/m | -$43M-201.5% | $465Mn/m |
| Gross Margin | 83.4% | 83.7%+0.3pp | 83.0%-0.7pp | 85.6%+2.6pp | 81.8%-3.8pp |
| Operating Margin | -83.9% | -75.7%+8.3pp | -15.4%+60.2pp | -7.9%+7.6pp | 13.5%+21.4pp |
| Net Margin | -101.0% | -109.0%-8.0pp | -24.1%+85.0pp | -12.4%+11.7pp | 8.4%+20.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net insider -$1.5M over 180 days (0 open-market buys, 6 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 16.8%/yr (revenue basis).
Base free cash flow $155M (avg FY2023–FY2025; latest year $465M) · equity value $22.4B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Avg target $324 (last qtr, 21 analysts) → $300 (last mo, 8) (-7.4%).
Buy-rated share 73% → 74% over ~3 months (+1pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Oct 2026 | $1.66 | $16.26 | +879.5% |
| Jul 2026 | $1.63 | $1.21 | -25.8% |
| Apr 2026 | $0.87 | $1.51 | +73.2% |
| Feb 2026 | $1.16 | $0.82 | -29.3% |
| Oct 2025 | $0.56 | $1.84 | +228.0% |
| Jul 2025 | $-0.54 | $-0.51 | +6.2% |
| May 2025 | $-0.89 | $-0.44 | +50.6% |
| Feb 2025 | $-0.62 | $-0.65 | -4.8% |
The QScore of 48 for Alnylam Pharmaceuticals indicates a neutral outlook, driven by a divergence between its long-term and short-term scores. The stock scores high on growth and profitability, with notable revenue growth of 65.2% and an ROE near 160%. However, it exhibits weak momentum, trading down 65.1% over the past year, and scores low on risk due to high volatility, which pulls down its overall score. The long-term score is 16 points higher than the short-term score, suggesting a potential disconnect between the company's fundamental strengths and its recent market performance.